LB Pharmaceuticals Press Releases

July 19, 2022LB Announces Publication of Phase 1 Clinical Study of LB-102
December 7, 2021LB Announces Presentation of Full Results of Dopamine Receptor Occupancy Study of LB-102 at the 2021 ACNP Conference
October 4, 2021LB Pharmaceuticals Presents Results of Dopamine Receptor Occupancy Studies of LB-102 at ECNP Conference
April 26, 2021LB Pharmaceuticals To Participate in the B. Riley Securities’ Neuroscience Conference
February 2, 2021LB Pharmaceuticals Announces the Initiation of Patient Dosing in Open Label Phase 1b Imaging Study of LB-102
September 25, 2020LB Pharmaceuticals Inc Secures $10.0 million in Additional Financing
September 14, 2020LB Pharmaceuticals Inc Announces Results of LB-102 First-in-Human Clinical Study
September 2, 2020LB Pharmaceuticals Inc Announces the Hiring of Dr. Anna Eramo as Chief Medical Officer
January 22, 2020 LB Pharmaceuticals Inc Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of LB-102, a Novel Benzamide for the Treatment of Schizophrenia
August 15, 2019 LB Pharmaceuticals Inc Announces the Publication of Its First Peer-Reviewed Manuscript
July 8, 2019LB Pharmaceuticals Inc Appoints Robert R. Ruffolo, Jr., Ph.D. to its Board of Directors
March 4, 2019 LB Pharmaceuticals Inc  Secures $8.4 Million in Series A Financing
January 1, 2019LB Pharmaceuticals Inc Announces Issuance of U.S. Patent Covering N-Methyl Amisulpride for the Treatment of Psychiatric Disorders

Want to stay in the loop?

Join our mailing list